# US 8,784,822 B2 · Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,784,822 B2
- Document ID: US8784822B2
- Status: Granted
- Kind: B2
- Application number: 12/367,643
- Filed: 2009-02-09
- Published: 2009-06-11
- Granted: 2014-07-22
- Earliest claimed: 2006-03-14
- Applicants: Boris Skurkovich; Ellen Millstein; Simon Skurkovich
- Inventors: Boris Skurkovich; Ellen Millstein; Simon Skurkovich
- Web page: https://patentgrep.com/patent/US8784822B2

## CPC

- C07K 16/18: against material from animals or humans
- A61P 13/12: of the kidneys
- C07K 16/241: {Tumor Necrosis Factors}
- C07K 16/245: {IL-1}
- C07K 16/248: {IL-6}
- C07K 16/249: {Interferons}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A method for treating renal failure associated with advanced stage renal disease includes administering a soluble cytokine receptor to one or more of tumor necrosis factor alpha, interferon gamma or interleukin 6; or antibodies to one or more of interleukin 6 or interleukin 1 beta. The method can be used as a supplement to or as partial or complete replacement for dialysis. A pharmaceutical composition includes antibody or functional equivalent thereof to urea, creatinine, or both; antibody, functional equivalent or soluble cytokine receptor to tumor necrosis factor alpha, interferon gamma, interleukin 6, interleukin 1 beta or any combination thereof. The composition can be included in a kit.

## Claims

### Claim 1

A method for treating a patient suffering from chronic renal failure, associated with elevated levels of one or more of tumor necrosis factor alpha, interferon gamma or interleukin 6, the method comprising administering to the patient a soluble cytokine receptor to the one or more of tumor necrosis factor alpha, interferon gamma or interleukin 6, wherein the soluble cytokine receptor is administered in an amount effective to reduce levels of the one or more of tumor necrosis factor alpha, interferon gamma or interleukin 6.

### Claim 2

A method for treating a patient suffering from chronic renal failure, associated with elevated levels of interleukin-6, interleukin 1 beta or both, the method comprising administering to the patient antibodies to interleukin 6, antibodies to interleukin 1 beta, or antibodies to interleukin 6 and antibodies to interleukin 1 beta, wherein the antibodies are administered in an amount effective to reduce levels of interleukin-6, interleukin 1 beta or both.

### Claim 3 (depends on 1)

The method of claim 1, wherein the patient is selected from a group of patients receiving dialysis according to a dialysis regimen.

### Claim 4 (depends on 2)

The method of claim 2, wherein the patient is selected from a group of patients receiving dialysis according to a dialysis regimen.